NASDAQ: LAB
Standard Biotools Inc Stock

$1.05+0.00 (+0%)
Updated Jun 13, 2025
LAB Price
$1.05
Fair Value Price
N/A
Market Cap
$398.81M
52 Week Low
$0.92
52 Week High
$2.41
P/E
-3.09x
P/B
0.88x
P/S
2.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$169.69M
Earnings
-$132.76M
Gross Margin
47%
Operating Margin
-76.11%
Profit Margin
-78.2%
Debt to Equity
0.28
Operating Cash Flow
-$111M
Beta
1.44
Next Earnings
Jul 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A

LAB Overview

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LAB's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Diagnostic & Research

Industry Rating
C
LAB
Ranked
#40 of 42

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$47.11A
$14.55A
$86.93B
View Top Diagnostic & Research Stocks

Be the first to know about important LAB news, forecast changes, insider trades & much more!

LAB News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LAB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LAB is good value based on its book value relative to its share price (0.88x), compared to the US Diagnostics & Research industry average (3.47x)
P/B vs Industry Valuation
LAB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LAB due diligence checks available for Premium users.

Valuation

LAB price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-3.09x
Industry
19.9x
Market
31.36x

LAB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.88x
Industry
3.47x
LAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LAB's financial health

Profit margin

Revenue
$40.8M
Net Income
-$26.0M
Profit Margin
-63.8%
LAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LAB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$579.6M
Liabilities
$125.0M
Debt to equity
0.28
LAB's short-term assets ($344.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LAB's short-term assets ($344.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LAB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$30.3M
Investing
$14.6M
Financing
-$46.0k
LAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LAB vs Diagnostic & Research Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LABD$398.81M0.00%-3.09x0.88x
MYGNC$463.65M-3.08%-4.49x0.66x
PSNLC$530.83M+3.44%-4.85x2.56x
CSTLD$541.36M-0.37%-125.00x1.23x
STIMC$249.46M-0.52%-2.87x7.04x

Standard Biotools Stock FAQ

What is Standard Biotools's quote symbol?

(NASDAQ: LAB) Standard Biotools trades on the NASDAQ under the ticker symbol LAB. Standard Biotools stock quotes can also be displayed as NASDAQ: LAB.

If you're new to stock investing, here's how to buy Standard Biotools stock.

What is the 52 week high and low for Standard Biotools (NASDAQ: LAB)?

(NASDAQ: LAB) Standard Biotools's 52-week high was $2.41, and its 52-week low was $0.92. It is currently -56.43% from its 52-week high and 14.13% from its 52-week low.

How much is Standard Biotools stock worth today?

(NASDAQ: LAB) Standard Biotools currently has 379,822,268 outstanding shares. With Standard Biotools stock trading at $1.05 per share, the total value of Standard Biotools stock (market capitalization) is $398.81M.

Standard Biotools stock was originally listed at a price of $14.02 in Feb 10, 2011. If you had invested in Standard Biotools stock at $14.02, your return over the last 14 years would have been -92.51%, for an annualized return of -16.9% (not including any dividends or dividend reinvestments).

How much is Standard Biotools's stock price per share?

(NASDAQ: LAB) Standard Biotools stock price per share is $1.05 today (as of Jun 13, 2025).

What is Standard Biotools's Market Cap?

(NASDAQ: LAB) Standard Biotools's market cap is $398.81M, as of Jun 15, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Standard Biotools's market cap is calculated by multiplying LAB's current stock price of $1.05 by LAB's total outstanding shares of 379,822,268.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.